COMPARISION OF MYO-INOSITOL VERSUS METFORMIN ON ANTHROPOMETRIC PARAMETERS IN POLYCYSTIC OVARIAN SYNDROME IN WOMEN
Objective: The objective of the study was to evaluate and compare the effect of insulin sensitizers i.e. metformin and myoinositol on anthropometric parameters in patients of the Polycystic ovarian syndrome (PCOS).
Methods: A prospective, open-labeled, randomized, comparative, clinical study was conducted on 60 patients. The patients were randomly divided into two groups of 30 each to receive either of the following two treatments: group A: Tablet myoinositol 1g twice daily. group B: Tablet metformin 500 mg thrice daily for 24 w. Anthropometric parameters were assessed by measuring body weight, Body mass index (BMI), waist circumference, hip circumference, waist-hip ratio (WHR) at baseline and subsequently at the end of 12 w and 24 w.
Results: In both the groups, there was a statistically significant improvement in over a period of 24 w. In group A, the values for weight at baseline, 12 w and 24 w expressed in meanÂ±SEM are 63.96Â±.90, 62.33Â±.88 and 61.20Â±.85 while in group B the values were 63.58Â±1.88, 62.26Â±1.74 and 60.86Â±1.65. In group A, the values for BMI at baseline, 12 w and 24 w were 26.45Â±.41, 25.78Â±.42 and 25.31Â±.40 while in group B the values were 26.09Â±.76, 25.53Â±.71 and 24.96Â±.68 respectively. In group A, WHR values were 0.79Â±.007, 0.78Â±.007 and 0.78Â±.007 while in group B 0.79Â±.010, 0.79Â±0.108, 0.79Â±.011 at baseline, 12 w and 24 w respectively. However, on comparing both the groups at 12 and 24 w, no statistically significant difference was observed in all the parameters.
Conclusion: There was a definite improvement in anthropometric parameters with both metformin and myoinositol but on comparing these drugs, no significant difference was observed. Thus, myoinositol can also be used as an alternative to metformin for the treatment of PCOS.
2. Hsu MI, Liou TH, Liang SJ, Su HW. Inappropriate gonadotropin secretion in polycystic ovary syndrome. Fertil Steril 2009;91:1168â€“74.
3. Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:162â€“8.
4. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation 2002;106:3143-6.
5. Rebuffe-Scrive M, Cullberg G, Lundberg PA. Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res 1989;21:391-7.
6. Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005;26:251â€“82.
7. Bringer J, Lefebvre P, Boulet F, Grigorescu F. Body composition and regional fat distribution in polycystic ovarian syndrome. Relationship to hormonal and metabolic profiles. Ann N Y Acad Sci 1993;687:115-23.
8. Bouchard C, Despres JP, Mauriege P. Genetic and non genetic determinants of regional fat distribution. Endoc Rev 1993;14:72-93.
9. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84:165â€“9.
10. Barbieri RL. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am J Obstet Gynecol 2000;183:1412â€“8.
11. Gennarelli G, Holte J, Berglund L, Berne C. Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod 2000;15:2098â€“102.
12. Nazari T, Bayat R, Hamedi M. Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial. Arch Iranian Med 2007;10:176â€“81.
13. Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomised double blind placebo controlled trial: effects of myoinositol on ovarian function and metabolic factors in women with PCOS. Eur Rev 2007;11:347-54.
14. Nehra J, Kaushal J, Singhal SR, Ghalaut VS. A comparative study of efficacy and safety of myoinositol versus metformin in polycystic ovarian syndrome in women. W J Pharm Pharm Sci 2016;5:884-96.
15. Legro RS, Castracane VD, Kauffman RP. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls. Obstet Gynecol Surv 2004;59:141-54.
16. Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF. Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8 y follow-up. Curr Diabetes Rep 2006;6:77-83.
17. Liou TH, Yang JH, Hsieh CH, Lee CY. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril 2009;92:1960â€“5.
18. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-4.
19. Awalekar J, Awalekar C, Jadhav VM, Chivate CG, Patwardhan MH. Effect of metformin and myoinositol and lifestyle modification in patients of polycystic ovarian disease (PCOD). Int J Biomed Reaser 2015;6:698-704.
20. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139-44.
21. Genazzani AD, Despini G, Santagni S, Prati A, Rattighieri E, Chierchia E, et al. Effects of a combination of alpha lipoic acid and myoinositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol Metabol Syndrome 2014;3:3.
22. Angik R, Jajoo SS, Hariharan C, Chimote A. A comparative study of metabolic and hormonal effects of myoinositol versus metformin in women with polycystic ovary syndrome: a randomized controlled trial. Int J Reprod Contracept Obstet Gynecol 2015;4:189-94.